MTVA on Nasdaq

MetaVia Inc.

We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases.³ From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerMTVA on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersCambridge, Massachusetts¹
Incorporated inDE²
Business address545 Concord Avenue, Suite 210, Cambridge, Ma 02138²
Filer categoryNon-accelerated filer, Smaller reporting company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income⁴⁵⁶⁷⁸⁹-$13.7M in 2025−32% since 2019

Net income⁴⁵⁶⁷⁸⁹-$13.0M in 2025−39% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31
Research and development	$6.8M	$21.6M
General and administrative	$6.9M	$7.3M
Total operating expenses	$13.7M	$28.8M
Loss from operations	-$13.7M	-$28.8M
Gain from change in fair value of warrant liabilities	$225.0K	$297.0K
Interest income, net	$510.0K	$920.0K
Total other income	$735.0K	$1.2M
Loss before income taxes	-$13.0M	-$27.6M
Provision for income taxes	$0	$0
Net loss	-$13.0M	-$27.6M
Loss per share of common stock, basic (in dollars per share)	-$7.35	-$39.13
Loss per share of common stock, diluted (in dollars per share)	-$7.35	-$39.13
Weighted average shares of common stock, basic (in shares)	1.8M shares	705.2K shares
Weighted average shares of common stock, diluted (in shares)	1.8M shares	705.2K shares

Total assets⁴⁵⁶⁷⁸⁹$11.1M in 2025−23% since 2019

Total liabilities⁴⁵⁶⁷⁸⁹$5.8M in 2025+166% since 2019

Shareholders’ equity⁵⁶⁷⁸⁹$5.3M in 2025−57% since 2019

Cash⁴⁵⁶⁷⁸⁹$10.3M in 2025−26% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁹

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$10.3M	$16.0M
Prepaid expenses and other current assets	$597.0K	$55.0K
Total current assets	$10.9M	$16.1M
Property and equipment, net	$17.0K	$34.0K
Right-of-use asset	$210.0K	$133.0K
Other assets	$21.0K	$21.0K
Total assets	$11.1M	$16.3M
Accounts payable	$1.1M	$3.9M
Clinical trial accrued liabilities	$79.0K	$1.7M
Accrued expenses and other current liabilities	$993.0K	$785.0K
Warrant liabilities	$136.0K	$361.0K	$658.0K
Related party payable	$3.3M	$1.5M
Lease liability, short-term	$68.0K	$78.0K
Total current liabilities	$5.6M	$8.3M
Lease liability, long-term	$142.0K	$58.0K
Total liabilities	$5.8M	$8.3M
Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2025 and 2024; 2,308,294 and 785,194 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$2.0K	$1.0K
Additional paid-in capital	$154.2M	$143.8M
Accumulated deficit	-$148.8M	-$135.9M
Total stockholders' equity	$5.3M	$7.9M	$16.7M
Total liabilities and stockholders' equity	$11.1M	$16.3M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100.0M shares	100.0M shares
Common stock, shares issued	2.3M shares	785.2K shares
Common stock, shares outstanding	2.3M shares	785.2K shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$10.3M	$16.0M
Prepaid expenses and other current assets	$597.0K	$55.0K
Total current assets	$10.9M	$16.1M
Property and equipment, net	$17.0K	$34.0K
Right-of-use asset	$210.0K	$133.0K
Other assets	$21.0K	$21.0K
Total assets	$11.1M	$16.3M
Accounts payable	$1.1M	$3.9M
Clinical trial accrued liabilities	$79.0K	$1.7M
Accrued expenses and other current liabilities	$993.0K	$785.0K
Warrant liabilities	$136.0K	$361.0K	$658.0K
Related party payable	$3.3M	$1.5M
Lease liability, short-term	$68.0K	$78.0K
Total current liabilities	$5.6M	$8.3M
Lease liability, long-term	$142.0K	$58.0K
Total liabilities	$5.8M	$8.3M
Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2025 and 2024; 2,308,294 and 785,194 shares issued and outstanding as of December 31, 2025 and 2024, respectively	$2.0K	$1.0K
Additional paid-in capital	$154.2M	$143.8M
Accumulated deficit	-$148.8M	-$135.9M
Total stockholders' equity	$5.3M	$7.9M	$16.7M
Total liabilities and stockholders' equity	$11.1M	$16.3M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100.0M shares	100.0M shares
Common stock, shares issued	2.3M shares	785.2K shares
Common stock, shares outstanding	2.3M shares	785.2K shares

Cash from operations⁴⁵⁶⁷⁸⁹-$15.7M in 2025+123% since 2019

Capital spending⁴⁵⁶⁸⁹$2.0K in 2025−99% since 2019

Free cash flow⁴⁵⁶⁸⁹-$15.7M in 2025+117% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31
Net loss	-$13.0M	-$27.6M
Stock-based compensation	$411.0K	$538.0K
Non-cash lease (credit) charge	-$3.0K	$4.0K
Depreciation	$19.0K	$20.0K
Gain from change in fair value of warrant liabilities	-$225.0K	-$297.0K
Prepaid expenses and other assets	-$542.0K	$20.0K
Accounts payable	-$2.8M	$3.1M
Accrued and other liabilities	$431.0K	-$461.0K
Net cash used in operating activities	-$15.7M	-$24.7M
Purchases of property and equipment	-$2.0K	-$8.0K
Net cash used in investing activities	-$2.0K	-$8.0K
Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering	$10.0M	$20.0M
Proceeds from exercise of warrants	$6.0K	$1.0K
Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units	-$12.0K	-$48.0K
Net cash provided by financing activities	$10.0M	$18.3M
Net decrease in cash and cash equivalents	-$5.7M	-$6.4M
Fair value of warrants issued to placement agent		$309.0K
Right-of-use assets obtained in exchange for operating lease liabilities	$152.0K

Compare MetaVia Inc. with another company

Leadership

Who has led MetaVia Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Charles Bisgaier Phd.2016–2019

President

Chief financial officer

Chief operating officer

Akash Bakshi2021

20202025

Chief executive officerJoseph Hooker Jan 18, 2023 to Jan 18, 2023¹²
Chief executive officerBen Gil Price Nov 4, 2021 to Nov 4, 2021¹³
Chief executive officerSteven R. Ph.d. Gullans May 31, 2017 to Jul 26, 2019¹⁴
Chief executive officerMina Sooch Aug 4, 2016 to Nov 29, 2016¹⁵
ChairCharles Bisgaier Phd. Aug 4, 2016 to Jul 26, 2019¹⁶
PresidentJoseph Hooker Jan 18, 2023 to Jan 18, 2023¹²
PresidentBen Gil Price Nov 4, 2021 to Nov 4, 2021¹³
PresidentSteven R. Ph.d. Gullans May 31, 2017 to Jul 26, 2019¹⁴
PresidentMina Sooch Aug 4, 2016 to Nov 29, 2016¹⁵
Chief financial officerMarshall H. Woodworth Oct 30, 2023 to now¹⁷
Chief financial officerJeffrey S. Mathiesen Aug 4, 2016 to Jan 30, 2018¹⁸
Chief operating officerAkash Bakshi Jan 5, 2021 to Jan 5, 2021¹⁹

Board members and other officers (24)

Chief Medical OfficerMark Versavel Dec 30, 2019 to Jan 2, 2020²⁰
VP, Clinical OperationsNicola Shannon Dec 30, 2019 to Dec 30, 2019²¹
VP of PreClinical R&D & Manf.Carmen Daniela Oniciu Aug 4, 2016 to Aug 12, 2016²²
Chief Commercial OfficerSeth Reno Aug 4, 2016 to Jul 26, 2019²³
Chief Medical OfficerLee Scott Golden Oct 6, 2016 to Jan 30, 2018²⁴
Board memberMark A. Glickman May 12, 2023 to now²⁵
Board memberJames Patrick Tursi Nov 2, 2023 to now²⁶
Board memberD. Gordon Strickland Feb 2, 2022 to now²⁷
Board memberAkash Bakshi Jan 5, 2021 to Jan 5, 2021¹⁹
Board memberAndrew I. Koven Jul 19, 2021 to now²⁸
Board memberJeong Gu Kang Jan 2, 2020 to Jun 10, 2022²⁹
Board memberJeong Gyun Oh Jan 2, 2020 to Jan 15, 2020³⁰
Board memberNa Yeon Kim Jan 2, 2020 to Jul 28, 2023³¹
Board memberDouglas J. Swirsky Sep 3, 2020 to Sep 3, 2020³²
Board memberJason L. Groves Dec 30, 2019 to now³³
Board memberMichael Salsbury Dec 30, 2019 to now³⁴
Board memberTae Heum Jeong Dec 30, 2019 to Jan 15, 2020³⁵
Board memberAndy Sassine Aug 4, 2016 to Jul 26, 2019³⁶
Board memberKenneth W. Kousky Aug 4, 2016 to Jul 26, 2019³⁷
Board memberMina Sooch Aug 4, 2016 to Nov 29, 2016¹⁵
Board memberP. Kent Hawryluk Aug 4, 2016 to Jan 30, 2018³⁸
Board memberPedro Lichtinger Aug 4, 2016 to Jul 26, 2019³⁹
Board memberSteven R. Ph.d. Gullans Aug 4, 2016 to Jan 15, 2020⁴⁰
General counselDavid Lowenschuss Aug 4, 2016 to Aug 12, 2016⁴¹

Named in SEC Form D filings

People the company listed in its private-offering notices.

Executive Officer, DirectorHyung Heon Kim named Oct 18, 2021 to May 15, 2025⁴²
Executive Officer, DirectorRichard J. Kang named Oct 18, 2021⁴³

Former names

NeuroBo Pharmaceuticals, Inc.Jan 2, 2020 to Nov 18, 2024²
Gemphire Therapeutics Inc.Apr 8, 2015 to Dec 31, 2019²

Timeline

Jan 18, 2023New chief executive Joseph Hooker becomes CEO¹²
Nov 4, 2021New chief executive Ben Gil Price becomes CEO¹³
May 31, 2017New chief executive Steven R. Ph.d. Gullans becomes CEO¹⁴
Aug 4, 2016New chief executive Mina Sooch becomes CEO¹⁵

Filings

291 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 115 major events, 60 insider forms, 17 large holders, 3 private raises, 76 other. The latest 20:

The 291 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 4 buys and 1 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Jun 4, 2025	Woodworth Marshall HChief Financial Officer	Buy	14,200	$0.70	$9.9K	Form 4
May 8, 2025	DONG-A ST CO., LTD10% owner	Buy	4,647,887	$0.71	$3.3M	Form 4
Sep 12, 2024	DONG-A ST CO., LTD10% owner	Sale	407	$3.75	$1.5K	Form 4
Jun 23, 2024	DONG-A ST CO., LTD10% owner	Buy	2,544,530	$3.93	$10.0M	Form 4
Jun 23, 2024	DONG-A ST CO., LTD10% owner	Buy	2,544,530	$3.13	$8.0M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Alyeska Investment Group, L.P.SCHEDULE 13G, 1 filing May 15, 2026⁴⁴
ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Nov 14, 2024 to Aug 14, 2025⁴⁵
DONG-A ST CO., LTDSCHEDULE 13D/A, 6 filings Sep 16, 2022 to May 20, 2025⁴⁶
Strategic Risk, LLC.SC 13G, 1 filing Mar 28, 2023⁴⁷
Altium Capital Management LLCSC 13G/A, 2 filings Nov 17, 2022 to Feb 14, 2023⁴⁸
JK BioPharma Solutions, IncSC 13D/A, 2 filings Nov 10, 2021 to Sep 23, 2022⁴⁹
E&Investment, Inc.SC 13D/A, 1 filing Aug 5, 2022⁵⁰

Money raised

Private offerings the company reported to the SEC on Form D.

May 8, 2025Raised $10 million in a private offering of equity Form D: 2 investors so far Form D
Jun 23, 2024Raised $17 million in a private offering of equity Form D: 2 investors so far Form D
Oct 1, 2021Raised $14 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jane Street Group, LLC	123,583	$176.7K	0.0%	+112,680
Citadel Advisors LLC	61,206	$87.5K	0.0%	New
Geode Capital Management, LLC	21,314	$30.5K	0.0%	−12,321
UBS Group AG	12,948	$18.5K	0.0%	+12,947
Scientech Research LLC	12,014	$17.2K	0.0%	New
Aries Wealth Management	10,000	$14.3K	0.0%	No change
Vanguard Capital Management LLC	8,919	$12.8K	0.0%	+6,697
Vanguard Fiduciary Trust Co	6,940	$9.9K	0.0%	No change
Tower Research Capital LLC (TRC)	2,223	$3.2K	0.0%	−379
SBI Securities Co., Ltd.	270	$386	0.0%	+65
Virtu Financial LLC	29,933	$43	0.0%	New
Morgan Stanley	10	$14	0.0%	New
BlackRock, Inc.	7	$10	0.0%	−472
Caitong International Asset Management Co., Ltd	3	$4	0.0%	No change
Brown Brothers Harriman & Co	2	$3	0.0%	No change
Danske Bank A/s	2	$3	0.0%	No change
International Assets Investment Management, LLC	2	$3	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMetaVia Inc. filings on SEC EDGAR
2
SEC EDGARMetaVia Inc. filings on SEC EDGAR
3
SEC EDGARMetaVia Inc. annual report, Item 1 (Business)
4
SEC EDGARMetaVia Inc. 10-K for fiscal 2019
5
SEC EDGARMetaVia Inc. 10-K for fiscal 2020
6
SEC EDGARMetaVia Inc. 10-K for fiscal 2021
7
SEC EDGARMetaVia Inc. 10-K for fiscal 2022
8
SEC EDGARMetaVia Inc. 10-K for fiscal 2023
9
SEC EDGARMetaVia Inc. 10-K for fiscal 2024
10
SEC EDGARMetaVia Inc. 10-Q for fiscal 2026
11
SEC EDGARMetaVia Inc. 10-Q for fiscal 2026
12
SEC EDGARJoseph Hooker, Chief executive officer
13
SEC EDGARBen Gil Price, Chief executive officer
14
SEC EDGARSteven R. Ph.d. Gullans, Chief executive officer
15
SEC EDGARMina Sooch, Chief executive officer
16
SEC EDGARCharles Bisgaier Phd., Chair
17
SEC EDGARMarshall H. Woodworth, Chief financial officer
18
SEC EDGARJeffrey S. Mathiesen, Chief financial officer
19
SEC EDGARAkash Bakshi, Chief operating officer
20
SEC EDGARMark Versavel, Chief Medical Officer
21
SEC EDGARNicola Shannon, VP, Clinical Operations
22
SEC EDGARCarmen Daniela Oniciu, VP of PreClinical R&D & Manf.
23
SEC EDGARSeth Reno, Chief Commercial Officer
24
SEC EDGARLee Scott Golden, Chief Medical Officer
25
SEC EDGARMark A. Glickman, Board member
26
SEC EDGARJames Patrick Tursi, Board member
27
SEC EDGARD. Gordon Strickland, Board member
28
SEC EDGARAndrew I. Koven, Board member
29
SEC EDGARJeong Gu Kang, Board member
30
SEC EDGARJeong Gyun Oh, Board member
31
SEC EDGARNa Yeon Kim, Board member
32
SEC EDGARDouglas J. Swirsky, Board member
33
SEC EDGARJason L. Groves, Board member
34
SEC EDGARMichael Salsbury, Board member
35
SEC EDGARTae Heum Jeong, Board member
36
SEC EDGARAndy Sassine, Board member
37
SEC EDGARKenneth W. Kousky, Board member
38
SEC EDGARP. Kent Hawryluk, Board member
39
SEC EDGARPedro Lichtinger, Board member
40
SEC EDGARSteven R. Ph.d. Gullans, Board member
41
SEC EDGARDavid Lowenschuss, General counsel
42
SEC EDGARMetaVia Inc. Form D naming Hyung Heon Kim
43
SEC EDGARMetaVia Inc. Form D naming Richard J. Kang
44
SEC EDGARAlyeska Investment Group, L.P. SCHEDULE 13G on MetaVia Inc.
45
SEC EDGARARMISTICE CAPITAL, LLC SCHEDULE 13G/A on MetaVia Inc.
46
SEC EDGARDONG-A ST CO., LTD SCHEDULE 13D/A on MetaVia Inc.
47
SEC EDGARStrategic Risk, LLC. SC 13G on MetaVia Inc.
48
SEC EDGARAltium Capital Management LLC SC 13G/A on MetaVia Inc.
49
SEC EDGARJK BioPharma Solutions, Inc SC 13D/A on MetaVia Inc.
50
SEC EDGARE&Investment, Inc. SC 13D/A on MetaVia Inc.